North America clinical trials market is projected to grow by 6.9% annually in the forecast period and reach $ 39,268.7 million by 2031, driven by the increasing number of clinical trials and increase in demand for novel therapies, rising prevalence on chronic diseases such as cancer and diabetes, the outbreak of tropical and infectious diseases such as COVID-19, and the increase in government initiatives and R&D investments.
Highlighted with 29 tables and 75 figures, this 136-page report “North America Clinical Trials Market 2021-2031 by Product Category (Drugs, Devices, Procedures), Phase (I, II, III, IV), Design (Interventional, Observational, Expanded Access), Service Type (Site Identification, Lab Services, Supply & Logistic, Decentralized Services), Indication (Oncology, Infectious Diseases, Cardiology, Obesity, Diabetes, Neurology), End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America clinical trials market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America clinical trials market in every aspect of the classification from perspectives of Product Category, Phase, Design, Service Type, Indication, End User, and Country.
Based on Product Category, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Trials of Drugs
o Small Molecule Drugs
o Vaccines
o Cell & Gene Therapy
o Other Drugs
• Trials of Devices
• Trials of Procedures
Based on Phase, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Phase I
• Phase II
• Phase III
• Phase IV
By Design, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Interventional Studies
o Randomized Control Trial
o Adaptive Clinical Trial
o Non-randomized Control Trial
• Observational Studies
o Cohort Study
o Case Control Study
o Cross Sectional Study
o Ecological Study
• Expanded Access Trials
By Service Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Protocol Designing
• Site Identification
• Patient Recruitment
• Laboratory Services
• Bioanalytical Testing Services
• Clinical Trial Data Management Services
• Clinical Trial Supply & Logistic Services
• Decentralized Clinical Trial Services
• Medical Device Testing Services
• Other Clinical Trial Services
By Indication, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Oncology
• Infectious Diseases
• Cardiology
• Obesity
• Diabetes
• Neurology
• Immunology
• Pain Management
• Other Indications
By End User, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Pharmaceutical and Biotechnological Companies
• Clinical Research Organizations
• Clinical Testing Laboratories
• Other End Users
Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Phase, Design, and Indication over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Accell Clinical Research LLC
Charles River Laboratory
ClinDatrix Inc
Clinipace
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
ICON PLC
IQVIA Holdings, Inc.
Laboratory Corporation of America
Novo Nordisk AS
PAREXEL International Corporation
Pfizer Inc.
Pharmaceutical Product Development LLC
PRA Health Sciences
Sanofi SA
SGS SA
Syneos Health Inc.
Wuxi AppTec Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 8
1.1 Industry Definition and Research Scope 8
1.1.1 Industry Definition 8
1.1.2 Research Scope 9
1.2 Research Methodology 12
1.2.1 Overview of Market Research Methodology 12
1.2.2 Market Assumption 13
1.2.3 Secondary Data 13
1.2.4 Primary Data 13
1.2.5 Data Filtration and Model Design 14
1.2.6 Market Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 24
2.2 Major Growth Drivers 26
2.3 Market Restraints and Challenges 33
2.4 Emerging Opportunities and Market Trends 36
2.5 Porter’s Fiver Forces Analysis 40
3 Segmentation of North America Market by Product Category 44
3.1 Market Overview by Product Category 44
3.2 Trials of Drugs 46
3.2.1 Small Molecule Drugs 47
3.2.2 Vaccines 48
3.2.3 Cell & Gene Therapy 49
3.2.4 Other Drugs 50
3.3 Trials of Devices 51
3.4 Trials of Procedures 52
4 Segmentation of North America Market by Phase 53
4.1 Market Overview by Phase 53
4.2 Phase I 55
4.3 Phase II 56
4.4 Phase III 57
4.5 Phase IV 58
5 Segmentation of North America Market by Design 59
5.1 Market Overview by Design 59
5.2 Interventional Studies 61
5.2.1 Randomized Control Trial 63
5.2.2 Adaptive Clinical Trial 64
5.2.3 Non-randomized Control Trial 65
5.3 Observational Studies 66
5.3.1 Cohort Study 68
5.3.2 Case Control Study 69
5.3.3 Cross Sectional Study 70
5.3.4 Ecological Study 71
5.4 Expanded Access Trials 72
6 Segmentation of North America Market by Service Type 73
6.1 Market Overview by Service Type 73
6.2 Protocol Designing 75
6.3 Site Identification 76
6.4 Patient Recruitment 77
6.5 Laboratory Services 78
6.6 Bioanalytical Testing Services 79
6.7 Clinical Trial Data Management Services 80
6.8 Clinical Trial Supply & Logistic Services 81
6.9 Decentralized Clinical Trial Services 82
6.10 Medical Device Testing Services 83
6.11 Other Clinical Trial Services 84
7 Segmentation of North America Market by Indication 85
7.1 Market Overview by Indication 85
7.2 Oncology 87
7.3 Infectious Diseases 88
7.4 Cardiology 89
7.5 Obesity 90
7.6 Diabetes 91
7.7 Neurology 92
7.8 Immunology 93
7.9 Pain Management 94
7.10 Other Indications 95
8 Segmentation of North America Market by End User 96
8.1 Market Overview by End User 96
8.2 Pharmaceutical and Biotechnological Companies 98
8.3 Clinical Research Organizations 99
8.4 Clinical Testing Laboratories 100
8.5 Other End Users 101
9 North America Market 2021-2031 by Country 102
9.1 Overview of North America Market 102
9.2 U.S. 105
9.3 Canada 108
9.4 Mexico 110
10 Competitive Landscape 112
10.1 Overview of Key Vendors 112
10.2 New Product Launch, Partnership, Investment, and M&A 116
10.3 Company Profiles 117
Accell Clinical Research LLC 117
Charles River Laboratory 119
ClinDatrix Inc 120
Clinipace 121
Eli Lilly and Company 122
F. Hoffmann-La Roche Ltd. 123
ICON PLC 124
IQVIA Holdings, Inc. 125
Laboratory Corporation of America 126
Novo Nordisk AS 127
PAREXEL International Corporation 128
Pfizer Inc. 129
Pharmaceutical Product Development LLC 130
PRA Health Sciences 131
Sanofi SA 132
SGS SA 133
Syneos Health Inc. 134
Wuxi AppTec Inc. 135
RELATED REPORTS 136
Selected Key Players:
Accell Clinical Research LLC
Charles River Laboratory
ClinDatrix Inc
Clinipace
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
ICON PLC
IQVIA Holdings, Inc.
Laboratory Corporation of America
Novo Nordisk AS
PAREXEL International Corporation
Pfizer Inc.
Pharmaceutical Product Development LLC
PRA Health Sciences
Sanofi SA
SGS SA
Syneos Health Inc.
Wuxi AppTec Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Ěý
Ěý
*If Applicable.
